Changes in Beneficial Ownership · 4
Sana Biotechnology, Inc.
SANANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primarydocument.xml
Filing details
- Report period
- 2026-08-26
- Issuer
- Sana Biotechnology, Inc.
- Issuer CIK
- 0001770121
- Trading symbol
- SANA
Reporting owner 1
- Name
- PATEL DHAVALKUMAR DHIRAJLAL
- Reporting owner CIK
- 0002115339
- Relationship
- Officer
- Officer title
- EVP, Chief Scientific Officer
- Address
- C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA, 98102
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-26 | M · Form 4 | 125,000.00 | A | 0.00 | 224,510.00 | D |
| Common Stock | 2026-08-27 | F · Form 4 | 41,158.00 | D | 4.11 | 183,352.00 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-08-26 | M · Form 4 | 125,000.00 | D | 0.00 | [F2] | [F2] | Common Stock | 125,000.00 | 250,000.00 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.↩ 1
- F2
- The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.↩ 1↩ 2
Signature 1
- Signed
- /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel
- Date
- 2026-08-27
Company context
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.